Commentary
Video
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
Author(s):
J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.
J. Bradley Elder, MD, director, Neurosurgical Oncology; professor, Department of Neurological Surgery, the Brain and Spine Tumor Center, The Ohio State University Wexner Medical Center, discusses blinded early-safety data from a phase 2b trial (NCT04485949) investigating the autologous cell immunotherapy IGV-001 in patients with newly diagnosed glioblastoma.
Related Videos
Related Content
